Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

This summary is generated by an algorithm. If you find any mistakes, let us know.

New Core Tech Raises USD 35M in Series C Funding
New Core Tech Raises USD 35M in Series C Funding
UN

Unicorn Nest news

New Core Tech Raises USD 35M in Series C Funding

– New Core Tech is a Shanghai, China-based manufacturing company.
– The company raised USD 35M in Series C funding.
– The round was led by XiaoMi, Shunwei Capital with participation from Northern Light Venture Capital and Cowin Capital.
– The new investment will be used to partnership and channel expansion and talent acquisition.

Source
Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors
Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors
UN

Unicorn Nest news

Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors

– Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1 and B2 financing.
– The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.
– In conjunction with this round of financing, Oceanpine CEO and managing partner Dave Chenn joins the Immune-Onc Board of Directors.

Source
Teon Therapeutics Completes $30 Million Series A Financing
Teon Therapeutics Completes $30 Million Series A Financing
UN

Unicorn Nest news

Teon Therapeutics Completes $30 Million Series A Financing

– Teon Therapeutics completed a $30m Series A financing.
– The financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives.
– All existing investors also participated in the financing round including Northern Light Venture Capital, Kaitai Capital and Oriental Fortune Capital.
– The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.

Source
1 2 3 58 59 60
Crunchbase icon

Content report

The following text will be sent to our editors: